PriceTargets.com logo

OmniAb - OABI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 157.14%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.50 As of 12/20/2024 06:16 PM ET
+0 (0.00%)

This chart shows the closing price for OABI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OmniAb Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OABI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OABI

Analyst Price Target is $9.00
▲ +157.14% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for OmniAb in the last 3 months. The average price target is $9.00, with a high forecast of $11.00 and a low forecast of $7.00. The average price target represents a 157.14% upside from the last price of $3.50.

This chart shows the closing price for OABI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in OmniAb. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024BenchmarkReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
11/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
8/19/2024BenchmarkReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
8/16/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$7.00 ➝ $7.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/14/2024BenchmarkReiterated RatingBuy ➝ Buy$8.00
3/26/2024Truist FinancialReiterated RatingBuy ➝ Buy$10.00
3/22/2024BenchmarkReiterated RatingBuy ➝ Buy$8.00
3/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00
3/21/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$7.00
11/29/2023Royal Bank of CanadaInitiated CoverageOutperform$6.00
11/14/2023BenchmarkReiterated RatingBuy ➝ Buy$8.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00
4/20/2023BenchmarkInitiated CoverageBuy$8.00
4/13/2023Craig HallumInitiated CoverageBuy$10.00
3/31/2023HC WainwrightReiterated RatingBuy$11.00
2/22/2023CowenInitiated CoverageOutperform$10.00
2/22/2023CowenInitiated CoverageOutperform$10.00
2/13/2023HC WainwrightInitiated CoverageBuy$11.00
12/20/2022Truist FinancialInitiated CoverageBuy$10.00
12/16/2022Credit Suisse GroupInitiated CoverageOutperform$13.00
11/29/2022Leerink PartnersInitiated CoverageOutperform$6.00
11/28/2022Stifel NicolausInitiated CoverageBuy$12.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2024
  • 3 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

OmniAb logo
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $3.50
Low: $3.50
High: $3.68

50 Day Range

MA: $4.01
Low: $3.50
High: $4.65

52 Week Range

Now: $3.50
Low: $3.43
High: $6.72

Volume

903,697 shs

Average Volume

504,929 shs

Market Capitalization

$494.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of OmniAb?

The following Wall Street research analysts have issued stock ratings on OmniAb in the last year: Benchmark Co., HC Wainwright, Royal Bank of Canada, and Truist Financial Co..
View the latest analyst ratings for OABI.

What is the current price target for OmniAb?

0 Wall Street analysts have set twelve-month price targets for OmniAb in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 157.1%. HC Wainwright has the highest price target set, predicting OABI will reach $11.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $7.00 for OmniAb in the next year.
View the latest price targets for OABI.

What is the current consensus analyst rating for OmniAb?

OmniAb currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OABI will outperform the market and that investors should add to their positions of OmniAb.
View the latest ratings for OABI.

What other companies compete with OmniAb?

Other companies that are similar to OmniAb include Applied Digital, LiveRamp, JOYY, Premier and Astrana Health. Learn More about companies similar to OmniAb.

How do I contact OmniAb's investor relations team?

OmniAb's physical mailing address is 65 EAST 55TH STREET 18TH FLOOR, NEW YORK NY, 10022. The company's listed phone number is 510-250-7800 and its investor relations email address is [email protected]. The official website for OmniAb is www.omniab.com. Learn More about contacing OmniAb investor relations.